Rosecliff Acquisition Corp I
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCLFW research report →
Price Chart
About the company
Rosecliff Acquisition Corp I functions as a Special Purpose Acquisition Company (SPAC), formed with the explicit goal of completing a corporate merger, acquiring another entity's assets or stock, engaging in a capital stock exchange, or orchestrating a reorganization with one or more businesses. This firm was established in 2020 and operates out of New York City.
- CEO
- Michael Patrick Murphy
- IPO
- 2021
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on RCLFW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $0
- P/E
- -4.70
- PEG
- 0.07
- P/S
- 3.44
- P/B
- -4.36
- EV/EBITDA
- -6.66
- Div Yield
- 0.00%
- Gross Margin
- 41.51%
- Op Margin
- -79.95%
- Net Margin
- -69.27%
- ROE
- 120.69%
- ROIC
- -288.36%
Latest fiscal year · YoY change
- Revenue
- $19.65M-33.6%
- Gross Profit
- $8.93M-32.8%
- Op Income
- $-8,603,000
- Net Income
- $-7,571,000+50.6%
- EPS
- $-0.29+65.9%
- OCF Growth
- -7.8%
- FCF Growth
- -7.8%
- 52W High
- $0.27
- 52W Low
- $0.20
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.00
- RSI (14)
- 65
- Avg Volume
- 0
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Spectral AI said Q2 was a transitional quarter, with burn FDA de novo clearance now in hand and a commercial rollout beginning under BARDA support, while 2026 revenue guidance remained unchanged at about $18.5 million.· August 11, 2026
- FDA de novo clearance for DeepView in burns is the big milestone, shifting the company from development toward commercialization.
- Management is targeting an initial U.S. rollout of up to 30 systems under the BARDA CLIN II/BioShield framework through June 30, 2027.
- The company expects the first 30 U.S. installations to be supported by BARDA, with recurring software and services revenue intended to build over time.
- Internationally, Spectral expects expanded UKCA clearance in Q4 and then initial placements in the U.K., Australia, or GCC countries.
- Leadership expanded with a new Chief Commercial Officer, and the company says it is building sales, procurement, and clinical relationships ahead of launches.
Q2 2026 R&D revenue was $3.5 million versus $5.1 million in Q2 2025. Gross margin was 31.6% versus 45.2% a year ago, and for the first six months gross margin was 41.8% versus 46.4%. Operating expenses were $5.4 million versus $4.4 million, and net loss was $4.2 million, or $0.13 per share, versus $8.0 million, or $0.31 per share. Adjusted EBITDA was $3.5 million versus $1.7 million. Cash was $14 million at June 30, 2026, versus $15.4 million at December 31, 2025, and total debt was $14.9 million. Management reiterated 2026 revenue guidance of approximately $18.5 million, including the effect of new BARDA funding from March, and said this guidance does not include any significant DeepView system sales.
Vincent Capone framed the quarter as a major turning point, emphasizing the FDA de novo clearance as validation of the technology and the start of Spectral’s transition to a commercial organization. He highlighted two revenue streams — device placement plus recurring software/services — and said the company is focused first on up to 30 BARDA-supported U.S. placements before expanding more broadly. His tone was optimistic and strategic, with repeated emphasis on the moat from the burn image library, patent portfolio, and the platform’s potential beyond burns.
David McGuire described Q2 as a transitional quarter as BARDA work moved into a cost-sharing phase and the company sat between major study phases. He said R&D revenue fell to $3.5 million from $5.1 million, gross margin declined to 31.6% from 45.2%, and operating expenses rose to $5.4 million, with G&A up mainly due to noncash stock compensation. He also noted that cash was $14 million, the second $6.5 million tranche of the Avenue Capital facility was drawn in June, the facility now totals $15 million, maturity is March 2028, and no principal payments are due until March 2027; he added that BARDA funding and a Yorkville equity facility provide additional flexibility.
Analysts focused on the commercial launch plan, asking about salesforce size, deployment hurdles, relationships with hospitals, the status of the MTEC handheld effort, and international expansion. Management said the salesforce currently includes two people, with budget for at least two more, and that procurement, AI committees, and cybersecurity reviews will be the main hurdles in some centers. On MTEC, Vince said the prototype was delivered and all contract items were completed, while internationally he said the U.K. and Australia look like the first likely adopters, with possible opportunities in the Middle East and GCC countries.
The clearest bull case is that Spectral has now crossed a meaningful regulatory hurdle with FDA de novo clearance, which management says validates the technology and unlocks commercialization. The company also has non-dilutive BARDA support for the first 30 U.S. placements, a cash balance of $14 million, and a longer runway thanks to the Avenue facility terms and no principal payments until March 2027.
The bear case is that revenue is still largely development-based and Q2 showed lower revenue and lower gross margin as BARDA shifted to cost-sharing and the company moved between study phases. Management also acknowledged that procurement, AI governance, and cybersecurity reviews may lengthen deployment cycles at some sites, and international sales timing is still uncertain despite expected UKCA expansion.
AI summary of the company's earnings call · Paraphrased · Not investment advice
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 28, 26 | DiMaio John Michael | other | 32,000 |
| Sep 23, 26 | DiMaio John Michael | other | 60,000 |
| Sep 21, 26 | DiMaio John Michael | other | 21,012 |
| Sep 18, 26 | DiMaio John Michael | other | 10,988 |
| Sep 11, 26 | DiMaio John Michael | other | 22,000 |
| Sep 10, 26 | DiMaio John Michael | other | 10,000 |
| Aug 13, 26 | DiMaio John Michael | other | 35,000 |
| Jun 29, 26 | DiMaio John Michael | other | 15,000 |
| Jun 25, 26 | DiMaio John Michael | other | 14,700 |
| Jun 24, 26 | DiMaio John Michael | other | 14,300 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RCLFW coverage
Recent articles, reports, and earnings notes.
No research on RCLFW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RCLFW report →